Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.74) per share. This is a 7.5 percent increase over losses of $(0.80) per share from the same period last year.
UNITY Biotechnology’s Wet AMD Candidate Flunks On Non-Inferiority Threshold Compared To Regeneron’s Drug
UNITY Biotechnology Inc (NASDAQ: UBX) announced results from Part A of the Phase 2 ENVISION study of UBX1325 in patients with wet age-related macular degeneration (AMD) who were not achieving optimum benefit with their ongoing anti-VEGF therapy.
